Clinical Trial to Assess Moxidectin Combination Treatment Options for LF
The DOLF team is currently conducting a randomized controlled trial in Cote d’Ivoire to study the safety and efficacy of moxidectin used in combination with diethylcarbamazine (DEC) and albendazole as a microfilaricide for LF.
Moxidectin (Mox) was approved by the U.S. FDA in June 2018 for treatment of onchocerciasis in persons at least 12 years of age. Clinical trials and animal studies have shown that Mox is a microfilaricide that temporarily suppresses microfilarial production and that it is superior to ivermectin for this purpose. However, no clinical trials have been performed to date to assess the efficacy of Mox (alone or in combination with DEC or Albendazole) for treatment of filarial parasites that cause LF(W. bancrofti or Brugia malayi).
This study will provide the first data on the relative safety and efficacy of IDA vs. MoxDA and on the relative efficacy of MoxA vs ivermectin plus albendazole (IA) for treatment of bancroftian filariasis. If the Mox combination treatments are safe and superior to the comparators for clearing Mf, they could improve chances for LF elimination in areas of Africa that are coendemic for LF and onchocerciasis (without loiasis).
Preliminary safety results will be available in early 2021 with primary efficacy results available in early 2023.